| SANGAMO THERAPEUTICS INC. |
| USA |
| Gesundheit |
| US8006771062 / 936386 |
| GBY (Frankfurt) / SGMO (NASDAQ) |
| FRA:GBY, ETR:GBY, GBY:GR, NASDAQ:SGMO |
| - |
| https://www.sangamo.com/ |
|
Sangamo Therapeutics Inc. is a biotechnology company focused on translating groundbreaking genomic therapies into transformative treatments for patients with genetic diseases. Specializing in proprietary zinc finger DNA-binding proteins (ZFPs), they ..
>Volltext.. |
| 103.65 Mio. EUR |
| 99.29 Mio. EUR |
| 28.57 Mio. EUR |
| -89.04 Mio. EUR |
| -94.64 Mio. EUR |
| -0.38 EUR |
| 22.09 Mio. EUR |
| 26.53 Mio. EUR |
| -66.18 Mio. EUR |
| 0.61 |
| -40.35% |
| 24.09% |
| - |
| - |
| - |
| - |
| SANGAMO |
| 31.03.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|